Geron (GERN) Total Non-Current Liabilities (2012 - 2026)
Geron's (GERN) quarterly Total Non-Current Liabilities came in at $191.5 million in Q2 2026, up 3.42% year-over-year from $185.1 million in Q2 2025, and down 1.63% quarter-over-quarter from $194.6 million in Q1 2026.
Analysis
Geron (GERN) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Geron has disclosed Total Non-Current Liabilities across 6 years of filings, most recently posting $191.5 million for Q2 2026.
- In Q2 2026, Total Non-Current Liabilities rose 3.42% year-over-year to $191.5 million; the TTM figure through Jun 2026 stood at $191.5 million (up 3.42% YoY), while the FY2025 annual figure was $232.5 million, up 11.24% from the prior year.
- Total Non-Current Liabilities came in at $191.5 million for Q2 2026 at Geron, down from $194.6 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $232.5 million in Q4 2025 to a low of $183.8 million in Q1 2025.
- Average Total Non-Current Liabilities over 3 years is $200.8 million, with a median of $194.6 million recorded in 2026.
- Year-over-year, Total Non-Current Liabilities climbed 11.24% in 2025 and climbed 3.42% in 2026.
- Over 3 years, Total Non-Current Liabilities stood at $209.0 million in 2024, then advanced by 11.24% to $232.5 million in 2025, then retreated by 17.66% to $191.5 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $191.5 million in Q2 2026, $194.6 million in Q1 2026, and $232.5 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 81.11 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 36.04 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 5.92 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 7.74 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 40.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 3.92 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 12.42 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 378.37 Mn |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | 191.46 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 191.46 Mn |
| Mar 31, 2026 | 194.63 Mn |
| Dec 31, 2025 | 232.53 Mn |
| Sep 30, 2025 | 208.63 Mn |
| Jun 30, 2025 | 185.14 Mn |
| Mar 31, 2025 | 183.83 Mn |
| Dec 31, 2024 | 209.04 Mn |
| Dec 31, 2014 | 41.78 Mn |
| Sep 30, 2014 | 7.07 Mn |
| Jun 30, 2014 | 4.47 Mn |
| Mar 31, 2014 | 4.37 Mn |
| Dec 31, 2013 | 7.22 Mn |
| Sep 30, 2013 | 6.58 Mn |
| Jun 30, 2013 | 4.95 Mn |
| Mar 31, 2013 | 6.77 Mn |
| Dec 31, 2012 | 14.10 Mn |